Donaciones. Patronos . Contacto. Diseño Web
(C) fehv. 2011. All rights reserved
1. Carreño V, Navarro A, Hernández-Guío C. Epidemiología de la hepatitis B. Rev Esp Enf Ap Dig 1979; 56: 589-596.
2. Carreño V, Navarro A, Hernández-Guío C. Hepatitis viral aguda en nuestro medio. Rev Soc And Pat Digest 1979; Tomo II: 207-214.
3. Carreño V, Navarro A, Hernández-Guío C. Virus de la hepatitis. Rev Esp Enf Ap Dig 1979; 56: 475-484.
4. Carreño V, Navarro A, Ortiz F, Hernández-Guío C. Virus de la hepatitis B y personal hospitalario. Rev Clin Esp 1980; 157: 179-182.
5. Aquino MA, Carreño V, Porres JC, Hernández-Guío C. Alteraciones hepáticas en los drogadictos. Gastroenterol Hepatol 1980; 4: 356-359.
6. García Mas JL, Carreño V, Hernández-Guío C. Valor de la GGTP en el estudio de las enfermedades hepatobiliares; su comparación con los parámetros bioquímicos habituales. Rev Esp Enf Ap Dig 1981; 59: 597-602.
7. Carreño V. Pronóstico, evolución y tratamiento de la hemocromatosis. Gastrum 1981; 6: 80-90.
8. Carreño V. Pronóstico, evolución y tratamiento de la CBP. Gastrum 1981; 6: 42-51.
9. Carreño V, Porres JC, Hernández‑Guío C, Marina Fiol C, Alvarez C, Hernando L. The significance of hepatitis B infection to nurses, paramedics and laboratory workers. Proc Eur Symp Hepatitis B. 1981; 27‑38. Ed. S. Krugman and S.Sherlock, MSD Int., Rahway.
10. Weller IVD, Carreño V, Fowler MJF, Monjardino J, Maniken D, Thomas HC, Sherlock S. Acyclovir inhibits hepatitis B virus replication in man. Lancet 1982; i: 273.
11. Weller IVD, Fowler MJF, Monjardino J, Carreño V, Thomas HC, Sherlock S. Inhibition of hepatitis B viral replication by lymphoblasted interferon. Phil Trans R Soc Lond (Biol) 1982; 299 (1094): 128-130.
12. Carreño V. Hepatitis viral aguda. Ed. Europharma. 1982; 5-15.
13. Carreño V. Virus No‑A,No‑B de la hepatitis: progresos realizados. Rev Clin Esp 1982; 167: 139-141.
14. Weller IVD, Carreño V, Fowler MJF, Monjardino J, Makinen D, Varghese Z, Sweny P, Thomas HC, Sherlock S. Acyclovir in hepatitis B antigen‑positive chronic liver diseases: inhibition of viral replication and transient renal impairment with iv bolus administration. J Antimicrobial Chemother 1983; 11: 223-231.
15. Montaño L, Carreño V, Ortiz O. Replicación viral y cambios en la expresión de los antígenos tisulares HBs y HBc en pacientes con hepatitis viral crónica tipo B. Rev Clin Esp 1983; 169: 99-101.
16. Carreño V, González R, Porres JC, Ortíz F, Martín F, Hernández‑Guio C. Prevalencia de anti‑HAV en la población española. Rev Esp Enf Ap Dig 1983; 64: 187-190.
17. Escuin F, Conesa J, Sanz A, Selgas R, Pérez M, Torres A, Ara JM, Gómez P, Carreño V, Lardinois R, Sánchez-Sicilia L. Vacunación contra hepatitis B en una unidad de diálisis. Nefrología 1983; 3: 287-293.
18. Carreño V, Montaño L, De Torres M. Tratamiento de la hepatitis crónica por virus B. Rev Clin Esp 1983; 171: 73-76.
19. Mora I, Porres JC, Carreño V. Marcadores serológicos del virus B de la hepatitis (VBH). Progresos realizados. Rev Clin Esp 1984; 173: 9-14.
20. Carreño V. Tratamiento de las hepatitis crónicas por virus B. Gastroenterol. Hepatol 1984 (Editorial); 7: 45-47.
21. Carreño V, Porres JC, Mora I, Hernández‑Guío C. Utilidad de la determinación de actividad DNA polimerasa del virus B de la hepatitis (VBH‑DNAp) en portadores crónicos de AgHBs. Rev Clin Esp 1984; 174: 75-77.
22. Porres JC, Carreño V, Hernández‑Guío C. Estudio prospectivo de hepatitis agudas por virus A, B y No‑A, No‑B: diferencias epidemiológicas y clínicas. Rev Clin Esp 1984; 174: 31-34.
23. Bas C, Carreño V, Porres JC, Mora I, Gutiez J, De Torres M, Hernández‑Guío C. Sobreinfección con agente delta en portadores crónicos de AgHBs en España. Características clínicas, epidemiológicas y virológicas. Rev Clin Esp 1984; 175: 67-69.
24. Carreño V, Porres JC, Gutiez J, Hernández‑Guío C. Reactivación vírica en hepatitis crónica por virus B con bajo nivel de replicación. Gastroenterol Hepatol 1984; 7: 461.
25. Carreño V, Alvarez Chiva V, Porres JC, Hernández‑Guío C, Hernando L. Patrón serológico de respuesta al virus B de la hepatitis en el personal sanitario. Gastroenterol Hepatol 1984; 7: 57-60.
26. Alvarez V, Carreño V, Plaza JJ, Mora I, Hernando L. Infección por virus de hepatitis en el transplante renal. Estudio prospectivo. Nefrología 1984; 4: 313-317.
27. Quiroga JA, Gonzalez O, Carreño V, Mora I, Porres JC, Gutiez J, Hernández‑Guío C. Radioimmunoassay for detecting hepatitis B core antigen in serum from patients with chronic hepatitis B infection. Clin Chem 1985; 31: 831-834.
28. Mora I, Porres JC, Carreño V. Receptores frente a albúmina humana polimerizada (RAHP): nuevos aspectos de la infección por el virus B de la hepatitis (VBH). Rev Clin Esp 1985; 176: 1-4.
29. Carreño V, Mora I, Escuin F, Sánchez Sicilia L, Alvarez V, Casado S, Alcázar JM, Hernando L, Porres JC, Carrasco JL, Lardinois R. Vaccination against hepatitis B in renal dialysis units: short or normal vaccination schedule?. Clin Nephrol 1985; 24: 215-220.
30. Salata H, Cortés JM, Enriquez de Salamanca R, Oliva H, Castro A, Kusak E, Carreño V, Hernández-Guío C. Porphyria cutanea tarda and hepatocellular carcinoma. Frequency of ocurrence and related factors. J Hepatol 1985; 1: 477-487.
31. Carreño V. Marcadores de replicación viral; su significado. Actualizaciones en Medicina Digestiva. Ed. Garsi 1986; 129-133.
32. Mora I, Carreño V, Porres JC, Gutiez J, Hernández‑Guío C. Relación entre la presencia de receptores frente a albúmina humana polimerizada (RAHP) y el nivel de replicación viral en la infección crónica por el virus B de la hepatitis (VBH). Rev Clin Esp 1986; 178: 278-282.
33. Bartolomé J, Castillo I, Carreño V, Mora I, Gutiez J, Porres JC, Hernández‑Guío C. Determinación del DNA del virus B de la hepatitis (VBH‑DNA) en portadores crónicos de AgHBs: relación con otros marcadores de replicación viral. Rev Clin Esp 1986; 178: 432-435.
34. Mora I, Porres JC, Hernández‑Guío C, Gutiez J, Carreño V. Hemagglutination and immunofluorescence studies on polymerized human serum albumin binding activity in chronic hepatitis B virus infection. Hepatology 1986; 6: 14-19.
35. Carreño V, Bartolomé J. Progresos en el conocimiento de la hepatitis por virus B: aporte de la biología molecular. Rev Clin Esp 1986; 178: 238-239.
36. Mora I, Porres JC, Bartolomé J, Hernández-Guio C, Gutiez J, Carreño V. Receptors for polymerized human serum albumin and other hepatitis B virus markers during acute hepatitis B; predictive value of the outcome of the disease. Hepato-Gastroenterol 1986; 33: 250-254.
37. Quiroga JA, Carreño V, Porres JC, Mora I, Gutiez J, Hernández-Guío C. Comparación entre la determinación de antígeno del core del virus B de la hepatitis (AgHBc) y actividad DNA polimerasa como marcadores de replicación vírica. Gastroenterol Hepatol 1986; 9: 363-366.
38. Carreño V, Gutiez J, Mora I, Porres JC, Hernández-Guío C. Estudio de poblaciones linfocitarias en pacientes con hepatitis por virus B: relación con otras etiologías. Rev Esp Enf Ap Dig 1986; 70: 493-496.
39. Mora I, Porres JC, Bartolomé J, Quiroga JA, Gutiez J, Hernández-Guío C, Bas C, Carreño V. Changes of hepatitis B virus (HBV) markers during prolonged recombinant interferon alpha-2A treatment of chronic HBV infection. J Hepatol 1987; 4: 29-36.
40. Mora I, Carreño V, Porres JC, Gutiez J, Hernández-Guío C. Hepatitis B surface antigen/IgM complexes: relation to receptors for polymerized human serum albumin, hepatitis B virus (HBV) DNA polymerase activity and HBV markers. Acta Virologica 1987; 31: 116-125.
41. Hernández-Guío C, Carreño V, Porres JC, Mora I. Hepatitis no-A, no-B. Rev Clin Esp 1987; 180: 100-103.
42. Quiroga JA, Bartolomé J, Porres JC, Mora I, Gutiez J, Hernández-Guío C, Carreño V. Identification of different degrees of hepatitis B virus (HBV) replicaction by serological (HBV-DNAp, HBcAg and HBV-DNA) and histological (HBcAg) methods. Liver 1987; 7: 169-175.
43. Mora I, Porres JC, Carreño V. Niveles mínimos de receptores para albúmnia humana polimerizada en la vacuna antihepatitis B derivada de plasma. Rev Clin Esp 1987; 181: 172.
44. Quiroga JA, Bartolomé J, Carreño V, Mora I, Porres JC, Gutiez J, Hernández-Guío C. Detección del anticuerpo de clase IgM contra el antígeno del core del virus B de la hepatitis en pacientes con infección crónica. Rev Clin Esp 1987; 181: 351-354.
45. Carreño V, Mora I. Combination of recombinant interferons alpha and gamma in treatment of chronic hepatitis B. Lancet 1987; ii: 1086.
46. Carreño V, Porres JC, Mora I, Gutiez J, Quiroga JA, Ramon y Cajal S, Oliva H, Compernolle C, Bartolomé J. A controlled study of treatment with recombinant interferon alpha in chronic hepatitis B virus infection: induction and maintenance schedules. Antiviral Res 1987; 8: 125-137.
47. Mora I, Porres JC, Carreño V. Receptors for polymerized human serum albumin in plasma derived hepatitis B vaccines. Vaccine 1987; 5: 279-282.
48. La Banda F, Carreño V. Tratamiento de la hepatitis crónica B. Gastroenterol Hepatol 1987; 10 (supl.1): 48-54.
49. Inglada L, Porres JC, La Banda F, Mora I, Carreño V. Anti-IFN-alpha titres during interferon therapy. Lancet 1987; ii: 1521.
50. Carreño V, Porres JC, Mora I, Bartolomé J, Bas C, Gutiez J, Cortés J, Hernández-Guío C. Prolonged (6 months) treatment of chronic hepatitis B virus infection with recombinant leukocyte A interferon. Liver 1987; 7: 325-332.
51. Bas C, Bartolomé J, Mora I, La Banda F, Porres JC, Hernández-Guío C, Carreño V. Prevalence of HBV-DNA among anti-HD positive patients. En: The hepatitis Delta virus and its infection, M. Rizzetto, J.L. Gerin, R.H. Purcell eds., Alan R. Liss ed., New York, NY. 1987; p 327-328.
52. De Torres M, Bas C, Bartolomé J, Porres JC, Hernández-Guío C, Carreño V. Liver membrane antibodies and delta superinfection. En: The hepatitis Delta virus and its infection, M. Rizzetto, J.L. Gerin, R.H. Purcell eds., Alan R. Liss ed., New York, NY. 1987; p 335.
53. Carreño V, La Banda F, Quiroga JA, Bartolomé J, Mora I. Terapia antiviral de la hepatitis crónica por virus B. En: Avances en Gastroenterología, M. Díaz-Rubio ed., Arán Ediciones S.A., Madrid. 1987; p 287-298.
54. De Torres M, Carreño V, Bartolomé J, Porres JC, Bas C, Quiroga JA, Mora I. Liver membrane antibodies in chronic delta hepatitis. Digestion 1987; 38: 171-177.
55. Quiroga JA, Mora I, Carreño V, Herrera MI, Porres JC, Gerlich WH. Inhibition of albumin binding to hepatitis B virions by monoclonal antibody to the preS2 domain of the viral envelope. Digestion 1987; 38: 212-220.
56. Bas C, Bartolomé J, La Banda F, Porres JC, Quiroga JA, Mora I, Hernández-Guío C, Carreño V. Infección por virus D de la hepatitis en portadores crónicos del virus B de la hepatitis: Relación con el sistema HBe. An Med Intern 1987; 4: 583-586.
57. La Banda F, Carreño V. Tratamiento de las hepatitis crónicas producidas por el virus B, delta y No-A, No-B. Bol Soc Gal Pato Digest 1987; 10: 15-30.
58. Porres JC, Mora I, Gutiez J, Bartolomé J, Quiroga JA, Bas C, Compernolle C, Ordi J, Chocarro A, Carreño V. Antiviral effect of recombinant gamma interferon in chronic hepatitis B virus infection: A pilot study. Hepato-Gastroenterol 1988; 35: 5-9.
59. La Banda F, Ruiz-Moreno M, Carreño V, Bartolomé J, Gutiez J, Ramón y Cajal S, Moreno A, Mora I, Porres JC. Recombinant a2-interferon treatment in children with chronic hepatitis B. Lancet 1988; i: 250.
60. Bas C, Bartolomé J, La Banda F, Porres JC, Quiroga JA, Mora I, Carreño V. Assessment of hepatitis B Virus DNA levels in chronic HBsAg carriers with or without hepatitis delta virus superinfection. J Hepatol 1988; 6: 208-213.
61. Ibarra MZ, Mora I, Quiroga JA, Bartolomé J, La Banda F, Porres JC, Carreño V. IgG and IgM auto-antiidiotype antibodies against antibody to HBsAg in chronic hepatitis B. Hepatology 1988; 8: 775-780.
62. Bartolomé J, Castillo I, Mora I, Gutiez J, Porres JC, Carreño V. Different levels of hepatitis B virus replication among hepatitis B e antigen positive chronic carriers. Acta Virol 1988; 32: 193-197.
63. Bartolomé J, Castillo I, Bas C, Mora I, Porres JC, Carreño V. Detección del DNA del virus B de la hepatitis en biopsias hepáticas de portadores crónicos de AgHBs. Rev Clin Esp 1988; 183: 67-70.
64. Gómez C, La Banda F, Porres JC, Mora I, Andrés A, Bartolomé J, Quiroga JA, Gutiez J, Castillo I, Bas C, Armenteros E, Ibarra MZ, Carreño V. Combined recombinant alpha and gamma interferon treatment of chronic hepatitis B virus infection. En: Viral Hepatitis and Liver Diseases, Alan R. Liss ed., New York, NY. 1988; 872-874.
65. Quiroga JA, Mora I, Porres JC, Carreño V. Elevation of 2',5'-Oligoadenylate synthetase activity and HLA-I associated ß2-microglobulin in response to recombinant interferon gamma administration in chronic HBeAg positive hepatitis. J Interferon Res 1988; 8: 755-763.
66. Porres JC, Carreño V, Mora I, Gutiez J, Moreno A, Ramón y Cajal S, Marrón JA, Bartolomé J. Different doses of recombinant interferon alpha in the treatment of chronic hepatitis B patients without antibodies against the human immunodeficiency virus. Hepato-Gastroenterol 1988; 35: 300-303.
67. Carreño V, Quiroga JA, Bartolomé J. Hepatitis: problemas pendientes. Bol Fund Jiménez Díaz 1988; 12: 36-37.
68. Carreño V, Castillo I, Mora I. Actualidad en el estudio de los marcadores del virus del SIDA. Bol Fund Jiménez Díaz. 1988; 12: 105-107.
69. Ruiz-Moreno M, García-Aguado J, Carreño V, Alvarez Sala L, Rincón P, López-Linares M, Bas C. Prevalencia de hepatitis por virus A, B y D en niños. An Esp Pediatr 1988; 29: 357-362.
70. Castillo I, Carreño V, Bartolomé J, Porres JC, Mora I, Herrera MI. Virus-like particles associated with reverse transcriptase activity in acute sporadic Non-A, Non-B hepatitis. Digestion 1989; 42: 7-15.
71. Porres JC, Carreño V, Bartolomé J, Gutiez J, Castillo I. A dynamic study of the intrafamilial spread of hepatitis B virus infection: relation with the viral replication. J Med Virol 1989; 28: 237-242.
72. Ruiz-Moreno M, Camps T, García J, Porres JC, Oliva H, Bartolomé J, Carreño V. Serological and histological follow-up of chronic hepatitis B infection. Arch Dis Child 1989; 64: 1165-1169.
73. Porres JC, Carreño V, Ruiz-Moreno M, Marrón JA, Bartolomé J. Interferon antibodies in patients with chronic HBV infection treated with recombinant interferon. J Hepatol 1989; 8: 351-357.
74. Ibarra MZ, Mora I, Bartolomé J, Porres JC, Carreño V. Detection of proteins encoded by the pre-S region of hepatitis B virus in the sera of HBsAg carriers: relation to viral replication. Liver 1989; 9: 153-158.
75. Porres JC, Carreño V, Bartolomé J, Moreno A, Galiana F, Quiroga JA. Treatment of chronic delta infection with recombinant human interferon alpha 2c at high doses. J Hepatol 1989; 9: 338-344.
76. Saldanha J, di Blas F, Bas C, Velosa J, Ramalho FM, di Marco V, Mora I, Carreiro de Moura M, Carreño V, Craxi A, Thomas HC, Monjardino J. Detection of hepatitis delta virus RNA in chronic liver disease. J Hepatol 1989; 9: 23-28.
77. Moraleda G, Bartolomé J, Madejón A, Martinez MG, Moreno E, Loinaz C, Gómez M, Carreño V. Influence of the positivity to HBV-DNA in serum, liver and peripheral mononuclear cells in the risk of HBV allograft infection after liver transplantation in HBsAg-positive recipients. Traspl Organs Tiss. 1989; 1: 19-22.
78. Moreno A, Ramón y Cajal S, Marazuela M, Carreño V, Milicua JM, Cerezo E, Cuesta C, Oliva H. Sanded nuclei in delta hepatitis. Liver 1989; 9: 367-371.
79. Quiroga JA, Carreño V. Interferon and hepatitis B vaccine in haemodialysis patients. Lancet 1989; i: 1264.
80. Ruiz-Moreno M, Jimenez J, Porres JC, Bartolomé J, Moreno A, Carreño V. A controlled trial of recombinant interferon alpha in caucasian children with chronic hepatitis B. Digestion 1990; 45: 26-33.
81. Bartolomé J, Moraleda G, Castillo I, Martínez MG, Porres JC, Carreño V. Presence of HBV-DNA in peripheral blood mononuclear cells from anti-HIV symtomless carriers. J Hepatol 1990; 10: 186-190.
82. Castillo I, Bartolomé J, Quiroga JA, Porres JC, Carreño V. Detection of HBeAg/anti-HBe immune complexes in the reactivation of hepatitis B virus replication among anti-HBe chronic carriers. Liver 1990; 10: 79-84.
83. Ibarra MZ, Porres JC, Bartolomé J, Escudero M, Quiroga JA, Carreño V. Changes in anti-idiotype antibodies against anti-HBs during recombinant interferon treatment of chronic hepatitis B. J Interferon Res 1990; 10: 367-373.
84. Porres JC, Hernández-Guío C, Carreño V. Avances realizados en el tratamiento de la hepatitis crónica por virus C. Rev Esp Enf Digest 1990; 77: 437-438.
85. Quiroga JA, Castillo I, Porres JC, Casado S, Sáez-Royuela F, Martínez MG, Gómez M, Inglada L, Sánchez-Sicilia L, Mora I, Galiana F, Barril G, Carreño V. Recombinant gamma interferon as adjuvant to hepatitis B vaccine in hemodialysis patients. Hepatology 1990; 12: 661-663.
86. Carreño V, Mora I, Quiroga JA, Bartolomé J, Bas C, Castillo I. Aspectos celulares y moleculares de la hepatitis vírica. En: Nuevas tendencias en Hepatología, M Cascales Ed., Madrid, CSIC. 1990.
87. Bartolomé J, Moraleda G, Molina J, Domínguez F, Porres JC, Carreño V. Hepatitis B virus DNA in liver and peripheral blood mononuclear cells during reduction in virus replication. Gastroenterology 1990; 99: 1745-1750.
88. Bartolomé J, Moraleda G, Ruíz-Moreno M, Porres JC, Carreño V. Hepatitis B virus DNA patterns in the liver of children with chronic hepatitis B. J Med Virol 1990; 31: 195-199.
89. Gómez Rubio M, Porres JC, Castillo I, Quiroga JA, Moreno A, Carreño V. Prolonged treatment (18 months) of chronic hepatitis C with recombinant a-interferon in comparison with a control group. J Hepatol 1990; 11 (S1): s63-s67.
90. Carreño V, Quiroga JA. Vacunas frente al virus de la hepatitis B. Problemas pendientes. Rev. Clin. Esp. 1990; 187: 247-248.
91. Moraleda G, Bartolomé J, Martínez MG, Porres JC, Carreño V. Influence of hepatitis delta virus replication in the presence of hepatitis B virus DNA in peripheral blood mononuclear cells. Hepatology 1990; 12: 1290-1294.
92. Madejón A, Castillo I, Bartolomé J, Melero M, Campillo ML, Porres JC, Moreno A, Carreño V. Detection of HDV-RNA by PCR in serum of patients with chronic HDV infection. J Hepatol 1990; 11: 381-384.
93. Carreño V, Saez-Royuela F, Gómez Rubio M. Use of recombinant interferon in the treatment of chronic non-A, non-B hepatitis: Results of two controlled trials. Proceedings of the IV International Symposium on Viral Hepatitis. Mediscript Ed. London (UK). (1990); 103-106.
94. Carreño V, Quiroga JA. Epidemiología y prevención de la hepatitis vírica en pacientes hemodializados. Gastroenterol Hepatol 1990; 13: 517-518.
95. Martínez MG, Castillo I, Quiroga JA, Porres JC, Carreño V. Detection of serum inhibitory factor for lymphocyte stimulation in chronic viral hepatitis: relationship with the replication level. Liver 1991; 11: 48-52.
96. Ruiz-Moreno M, Rúa MJ, Carreño V, Quiroga JA, Manns M, Meyer zum Büschenfelde KH. Autoimmune chronic hepatitis type 2 manifested during interferon therapy in children. J Hepatol 1991; 12: 265-266.
97. Saez-Royuela F, Porres JC, Moreno A, Castillo I, Martinez G, Galiana F, Carreño V. High doses of recombinant alpha interferon or gamma interferon for chronic hepatitis C: a randomized controlled trial. Hepatology 1991; 13: 327-331.
98. Castillo I, Bartolomé J, Madejón A, Melero M, Porres JC, Carreño V. Hepatitis delta virus RNA detection in chronic HBsAg carriers with and without HIV infection. Digestion 1991; 48: 149-156.
99. Ruiz-Moreno M, Rua MJ, Molina J, Moraleda G, Moreno A, García-Aguado J, Carreño V. Prospective randomized controlled trial of alpha interferon in children with chronic hepatitis B. Hepatology 1991; 13: 1035-1039.
100. Carreño V, Quiroga JA. Treatment of chronic hepatitis B with alpha interferon: Present and future. J Hepatol 1991; 13: S2.
101. Quiroga JA, Campillo ML, Castillo I, Bartolomé J, Porres JC, Carreño V. IgM antibody to hepatitis C virus in acute and chronic hepatitis C. Hepatology 1991; 14: 38-43.
102. Diez A, Quiroga JA, Melero M, Moraleda G, Castillo I, Porres JC, Carreño V. Detection of antibody to calmodulin in chronic viral hepatitis: lack of correlation with virus replication and hepatocellular damage. Digestion 1991; 49: 125-133.
103. Carreño V, Porres JC, Ruiz-Moreno M, Gutiez J, Bartolomé J. Estudio controlado de tratamiento con interferon alfa recombinante en la hepatitis crónica por virus B en la infancia. Rev Esp Enf Digest 1991; 79: 24-28.
104. Escudero MM, Quiroga JA, Bartolomé J, Carreño V. Analysis of serum pre-S antigens in chronic hepatitis B virus infection in relation to the expression pattern of hepatitis B virus DNA in the liver. Digestion 1991; 49: 204-211.
105. Moraleda G, Bartolomé J, Molina J, Castillo I, Carreño V. Analysis of hepatitis B virus DNA, liver disease and influence of antibody to hepatitis C virus in anti-HBe chronic carriers. Liver 1991; 11: 352-357.
106. Porres JC, Carreño V, Moreno A, Bartolomé J. Reactivación del virus B de la hepatitis en portadores crónicos con anti-HBe. Rev Clin Esp 1991; 189: 68-72.
107. Thomas HC, Dusheiko GM, Lok ASF, Farrell GC, Williams SJ, Cooksley WGE, Pérez V, Tanno H, Carreño V, Ryff JC. Comparative study of three doses of interferon alpha-2A in chronic active hepatitis B. En: Viral Hepatitis and Liver Disease. F.B. Hollinger, S.M. Lemon, H. Margolis, eds. Williams and Wilkins, Baltimore, MD, 1991: 641-642.
108. Campillo ML, Quiroga JA, Bartolomé J, Moraleda G, Castillo I, Carreño V. Protein composition of hepatitis B virus e antigen in the natural course of the disease and following interferon therapy. J Clin Microbiol 1992; 30: 1256-1261.
109. Carreño V, Tapia L, Ryff JC, Quiroga JA, Castillo I. Treatment of chronic hepatitis C by continuous subcutaneous infusion of interferon-alpha. J Med Virol 1992; 37: 215-219.
110. Ortiz A, Quiroga JA, García Delgado R, Carreño V, Caramelo C. Virus de la hepatitis C y crioglobulinemia. Rev Clín Esp 1992; 190: 157.
111. Ruiz-Moreno M, Rúa MJ, Castillo I, García-Novo MD, Santos M, Navas S, Carreño V. Treatment of children with chronic hepatitis C with recombinant alpha interferon: a pilot study. Hepatology 1992; 16: 882-885.
112. Castillo I, Bartolomé J, Quiroga JA, Carreño V. Comparison of several PCR procedures for detection of HCV RNA using different regions of the HCV genome. J Virol Methods 1992; 38: 71-80.
113. Caramelo C, Carreño V, González-Parra E, Quiroga JA, Garrón MP, Marriott E, Ortíz A, Galera A, López MD, Porres JC. Positive ELISA-2 is pathologically relevant in ELISA-1-negative patients on hemodialysis. Nephron 1992; 61: 474.
114. Marriott E, Quiroga JA, Carreño V. Re-Treatment of chronic hepatitis C with alpha-interferon. J Infect Dis 1992; 166: 1200-1.
115. Ruíz-Moreno M, Carreño V, Rúa MJ, Cotonat T, Serrano B, Santos M, Marriott E. Increase in triglicerides during alpha interferon treatment of chronic viral hepatitis. J Hepatol 1992; 16: 384.
116. Carreño V, Castillo I, Molina J, Porres JC, Bartolomé J. Long-term follow-up of hepatitis B chronic carriers who responded to interferon therapy. J Hepatol 1992; 15: 102-106.
117. Quiroga JA, Bosch O, Gonzalez R, Marriott E, Castillo I, Bartolomé J, Carreño V. Immunoglobulin M antibody to hepatitis C virus during interferon therapy for chronic hepatitis C. Gastroenterology 1992; 103: 1285-1289.
118. Ruiz-Moreno M, Rúa MJ, Moraleda G, Guardia L, Moreno A, Carreño V. Treatment with interferon gamma versus interferons alfa and gamma in children with chronic hepatitis B. Pediatrics 1992; 90: 254-258.
119. Molina J, Bartolomé J, Moraleda G, Ruiz-Moreno M, Rúa MJ, Moreno A, Carreño V. Persistence of hepatitis B virus DNA after eduction of viral replication in serum and liver. J Med Virol 1992; 38: 11-15.
120. Bosch O, Tapia L, Quiroga JA, Carreño V. An escalating dose regime of recombinant interpheron-alpha 2A in the treatment of chronic hepatitis C. J Hepatol 1993; 17: 146-149.
121. Bartolomé J, Castillo I, Quiroga JA, Navas S, Carreño V. Detection of hepatitis C virus RNA in serum and peripheral blood mononuclear cells. J Hepatol 1993; 17: s90-s93.
122. Moreno A, Martinez CJ, Carreño V. Liver biopsy and the etiologic diagnosis of chronic hepatitis. J Hepatol 1993; 17: s112-s115.
123. Moreno-González E, Loinaz C, García I, Lumbreras C, Gómez R, Moraleda G, Pinto IG, Colina F, Jiménez C, Carreño V, Bercedo J, Ibañez J, Alberti N, Maffettone V. Liver transplantation in chronic viral B and C hepatitis.J Hepatol 1993; 17: s116-122.
124. Carreño V, Marriott E, Quiroga JA. Other approaches to the treatment of chronic viral hepatitis. J Hepatol 1993; 17: s127-s129.
125. Madejón A, Castillo I, Cotonat T, Carreño V. Significance of low HDV replication levels during the natural history of HDV infection. J Hepatol 1993; 17: s157-s160.
126. Navas S, Castillo I, Carreño V. Detection of plus and minus HCV-RNA in normal liver of anti-HCV positive patients. Lancet 1993; 341: 904-905.
127. Carreño V. Ultimos avances en hepatología. Hepatol Clin 1993; 1: 71-82.
128. Carreño V, Moreno A, Galiana F, Bartolomé J. Alpha and gamma interferon versus alpha interferon alone in chronic hepatitis B. A randomized controlled trial. J Hepatol 1993; 17: 321-325.
129. Marriott E, Navas S, del Romero J, García S, Castillo I, Quiroga JA, Carreño V. Treatment with recombinant alpha-interferon of chronic hepatitis C in anti-HIV positive patients. J Med Virol 1993; 40: 107-111.
130. Carreño V. Ultimos avances en hepatología. Hepatol ClIn 1993; 1: 149-162.
131. Ruiz-Moreno M, García R, Rúa MJ, Serrano B, Moraleda G, Feijoo E, Bartolomé J, Ortiz F, Castillo I, Carreño V. Levamisole and interferon in children with chronic hepatitis B. Hepatology 1993; 18: 264-269.
132. Carreño V, Quiroga JA. Ultimos avances en hepatología. Hepatol Clin 1993; 1: 224-244.
133. Bosch O, Moraleda G, Castillo I, Carreño V. Treatment of chronic hepatitis B with recombinant interferon alpha versus recombinant interferon alpha plus levamisole. J Hepatol 1993; 19: 437-441.
134. Martín J, Bosch O, Moraleda G, Bartolomé J, Quiroga JA, Carreño V. Pilot study of recombinant human granulocyte-macrophage colony-stimulating factor in the treatment of chronic hepatitis B. Hepatology 1993; 18: 775-780.
135. Caramelo C, Ortiz A, Aguilera B, Porres JC, Navas S, Marriott E, Alberola ML, Alamo C, Galera A, Garron MP, González-Parra E, Fernández de Gabriel MV, Oliva H, Carreño V. Liver disease patterns in hemodialysis patients with antibodies to hepatitis C virus. Am J Kidney Dis 1993; 22: 822-828.
136. Carreño V. Virus C de la hepatitis: vacunación y tratamiento problemáticos. Rev Clin Esp 1993; 192: 155-156.
137. Carreño V, Hernández-Guío C, Bartolomé J, Quiroga JA. Cambios en los niveles séricos de la actividad 2',5'-oligoadenilato sintetasa, ß2-microglobulina y neopterina durante el aclaramiento del virus B de la hepatitis con o sin agudización en las transaminasas. Rev Esp Enf Digest 1993; 83: 169-175.
138. Carreño V, Bartolomé J, Castillo I. Ultimos avances en hepatología. Hepatol Clin 1993; 1: 335-354.
139. Alberola ML, Caramelo C, Navas S, Garrón MP, Aguilera B, Carreño V, Bermejillo T, Reyero R, Galera A, Marriott E, Ortiz A, Alcázar R, Alamo C, Porres JC. Infección por virus C de la hepatitis en pacientes en hemodiálisis y en receptores de transplante renal. Hepatol Clin 1993; 1: 185-193.
140. Ortiz A, Quiroga JA, García Delgado R, Carreño V, Caramelo C. Virus de la hepatitis C y crioglobulinemia. Rev Clín Esp 1993; 192: 157.
141. Carreño V, Bartolomé J, Castillo I. Long-term effect of interferon therapy in chronic hepatitis B. J Hepatol 1994; 20: 431-435.
142. Carreño V, Pardo M. Tratamiento de la hepatitis crónica por VBH y VDH. Rev. And Patol Digest 1994; 17: 17-21.
143. Caramelo C, Navas S, Alberola ML, Bermejillo T, Reyero A, Carreño V. Evidence against transmission of hepatitis C virus through hemodialysis ultrafiltrate and peritoneal fluid. Nephron 1994; 66: 470-473.
144. Carreño V. Ultimos avances en hepatología. Hepatol Clin 1994; 2: 47-74.
145. Madejón A, Cotonat T, Bartolomé J, Castillo I, Carreño V. Treatment of chronic hepatitis D virus infection with low and high doses of interferon-alpha 2a: Utility of polymerase chain reaction in monitoring antiviral response. Hepatology 1994; 19: 1331-1336.
146. Castillo I, Bartolomé J, Navas S, Gonzalez S, Herrero M, Carreño V. Virological and biochemical long-term follow-up of patients with chronic hepatitis C treated with interferon. Hepatology 1994; 19: 1342-1346.
147. Pardo M, Cotonat T, Herrero M, Marriott E, Artillo S, Quiroga JA, Carreño V. Retreatment of chronic hepatitis C virus infection. Lancet 1994; 343: 1568-1569.
148. Navas S, Castillo I, Bartolomé J, Marriott E, Herrero M, Carreño V. Positive and negative hepatitis C virus RNA strands in serum, liver and peripheral blood mononuclear cells in anti-HCV patients: Relation with the liver lesion. J Hepatol 1994; 21: 182-186.
149. Pardo, Carreño V. Lack of efficacy of inosine pranobex in the treatment of chronic hepatitis C. J Hepatol 1994; 21: 278.
150. López-Alcorocho JM, Moraleda G, Bartolomé J, Castillo I, Cotonat T, Aguilar J, Ortega E, Pons JA, Salmerón J, Vázquez-Iglesias JL, Carreño V. Analysis of hepatitis B precore region in serum and liver of chronic hepatitis B virus carriers. J Hepatol 1994; 21: 353-360.
151. Quiroga JA, Herrero M, Castillo I, Navas S, Pardo M, Carreño V. Long-term follow-up study of serum IgM antibody to hepatitis C virus (HCV), HCV replication and liver disease outcome in chronic hepatitis C. J Infect Dis 1994; 170: 669-673.
152. Carreño V, Quiroga JA. Hepatitis viral aguda. En: Tratado de Medicina Interna, Sección XI, Capítulo 5. M. Díaz Rubio, D. Espinós Eds. Editorial Panamericana, Madrid, 1994; 1384-1396
153. Krogsgaards K, Bindslev N, Christensen E, Craxi A, Schlichting P, Schalm S, Carreño V, Trepo C, Gerken G, Thomas HC, Andersen PK, Ring-Larsen H and the European Concerted Action on Viral Hepatitis (Eurohep). The treatment effect of alpha interferon in chronic hepatitis B is independent of pre-treatment variables. Results based on individual patient data from 10 clinical controlled trials. J Hepatol 1994; 21: 646-655.
154. Carreño V, Bartolomé J, Castillo I. Ultimos avances en hepatología. Hepatol Clin 1994; 2: 131-160.
155. Quiroga JA, Martín J, Pernas M, Pardo M, Herrero M, Castillo I, Bartolomé J, Carreño V. Evidence of Subtype-Specific Antibodies to Antigenic Epitopes in the NS5 Region of Hepatitis C Virus in the Circulation of Patients with Chronic Hepatitis C. Clin Diag Lab Immunol 1994; 1: 545-551.
156. González Parra E, Bermejillo T, Martín J, Aguilera B, Ortiz A, Fernández de Gabriel MV, Carreño V, Caramelo C. Niveles de interferón recombinante humano alfa 2b en pacientes en hemodiálisis. Nefrología 1994; 14: 207-210
157. Martín J, Quiroga JA, Bosch O, Carreño V. Changes in cytokine production during therapy with granulocyte-macrophage colony-stimulating factor in patients with chronic hepatitis B. Hepatology 1994; 20: 1156-1161.
158. Carreño V. Ultimos avances en hepatología. Hepatol Clin 1994; 2: 201-228.
159. Quiroga JA, Martín J, Pardo M, Carreño V. Serum levels of soluble immune factors and pathogenesis of chronic hepatitis C, and their relation to therapeutic response to alpha-interferon. Dig Dis Sci 1994; 39: 2485-2496.
160. Carreño V, Bartolomé J, Madejón A. Hepatitis delta virus infection: Molecular biology and treatment. Dig Dis 1994; 12: 265-275.
161. Carreño V, Castillo I, Quiroga JA. Ultimos avances en hepatología. Hepatol Clin 1994; 2: 275-308.
162. Thomas HC, Lok ASF, Carreño V, Farrell G, Tanno H, Pérez V, Dusheiko GM, Cooksley G, Ryff JC and the International Hepatitis Trial Group. Comparative study of three doses of interferon-alpha 2a in chronic active hepatitis B. J Viral Hepatitis 1994; 1: 139-148.
163. Pernas M, Bartolomé J, Castillo I, Quiroga JA, Pardo M, Carreño V. Sequence of non-structural regions 3 and 5 of hepatitis C virus genomes from Spanish patients: existence of a predominant variant related to type 1b. J Gen Virol 1995; 76: 415-420.
164. Navas S, Bosch O, Castillo I, Marriott E, Carreño V. Porphyria cutanea tarda and hepatitis C and B viruses infection: A retrospective study. Hepatology 1995; 21: 279-284.
165. González S, Navas S, Madejón A, Bartolomé J, Castillo I, Moraleda G, Martín J, Marriott E, Herrero M, Carreño V. Hepatitis B and D genomes in hepatitis B surface antigen negative patients with chronic hepatitis C. J Med Virol 1995; 45: 168-173.
166. Bartolomé J, Madejón A, Carreño V. Ribozymes: structure, characteristics and use as potential antiviral agents. J Hepatol 1995; 22: s57-s64.
167. Navas S, Carreño V. Semiquantification by AmplicorTM assay of hepatitis C virus genome during therapy. J Hepatol 1995; 22: s115-s117.
168. Carreño V, Quiroga JA. Biologic response modifiers in chronic hepatitis C. J Hepatol 1995; 22: s122-s126.
169. Carreño V, Quiroga JA, Castillo I. Ultimos avances en hepatología. Hepatol Clin. 1995; 3: 39-66.
170. Pardo M, Castillo I, Navas S, Carreño V. Treatment of chronic hepatitis C with cirrhosis with recombinant human granulocyte colony-stimulating factor plus recombinant interferon alpha. J Med Virol 1995; 45: 439-444.
171. Ruíz-Moreno M, Camps T, Jiménez J, López R, Castillo I, Bartolomé J, Carreño V. Factors predictive of response to interferon therapy in children with chronic hepatitis B. J Hepatol 1995; 22: 540-544.
172. Carreño V. Castillo I. Ultimos avances en hepatología. Hepatol Clin 1995; 3: 91-118.
173. Castillo I, Bartolomé J, Ruiz-Moreno M, Sánchez V, Navas S, Carreño V. Hepatitis C virus genotypes in serum and liver of children with chronic hepatitis C. Pediatric Res 1995; 38: 618-620.
174. Pardo M, Marriott E, Moliner MC, Quiroga JA, Carreño V. Risk and benefits of interferon-alpha in the treatment of hepatitis. Drug Safety 1995; 13: 304-316.
175. Quiroga JA, van Binsbergen J, Wang CY, Pardo M, Navas S, Trines Ch, Herrero M, Carreño V. Immunoglobulin M antibody to hepatitis C virus core antigen: Correlations with viral replication, histological activity and liver disease outcome. Hepatology 1995; 22: 1635-1640.
176. Carreño V, Bartolomé J, Castillo I. Ultimos avances en hepatología. Hepatol Clin 1995; 3: 223-240.
177. López-Alcorocho JM, Cabrerizo M, Bartolomé J, Cotonat T, Carreño V. Analysis of hepatitis B virus precore variants in hepatitis B e antibody-positive patients treated with prednisone plus interferon. J Viral Hepatitis 1995; 2: 279-284.
178. Quiroga JA, Pardo M, Navas S, Martín J, Carreño V. Patterns of immune responses to the host-encoded GOR and hepatitis C virus core-derived epitopes with relation to hepatitis C viremia, genotypes and liver disease severity. J Infect Dis 1996; 173: 300-305.
179. Martín J, Navas S, Quiroga JA, Carreño V. Recombinant human granulocyte colony-stimulating factor reduces hepatitis C virus replication in mononuclear cells from chronic hepatitis C patients. Cytokine 1996; 8: 313-317.
180. Carreño V, Parra A, Navas S, Quiroga JA. Granulocyte-Macrophage Colony-Stimulating Factor as Adjuvant Therapy for Interferon-a Treatment of Chronic Hepatitis C. Cytokine 1996; 8: 318-322.
181. Carreño V. Ultimos avances en hepatología. Hepatol Clin 1996; 4: 47-70.
182. Carreño V, Quiroga JA. New and forthcoming therapies for viral hepatitis. J Hepatol 1996; 24 (Suppl. 2): s74-s76.
183. Cabrerizo M, Bartolomé J, Ruíz-Moreno M, Otero M, López-Alcorocho JM, Carreño V. Distribution of the predominant hepatitis B virus precore variants in hepatitis B e antigen-positive children and their effect on treatment response. Pediatric Res. 1996; 39: 980-984.
184. Carreño V. Ultimos avances en hepatología. Hepatol Clin 1996; 4: 125-142.
185. Quiroga JA, Cotonat T, Castillo I, Carreño V. Hepatitis E virus seroprevalence in acute viral hepatitis in a developed country confirmed by supplemental assay. J Med Virol 1996; 50: 16-19.
186. García-Trevijano ER, López-Alcorocho JM, Quintana M, Hernández F, Carreño V. HGV in coagulation-factor concentrates. Lancet 1996; 348: 1032.
187. Madejón A, Carreño V. Virus delta de la hepatitis. En: Tratado de Hepatología, Tomo I, Sección IV: Hepatitis Virales, Capítulo 29. J.M. Herrerías, A. Díaz, M. Jiménez Eds. Sevilla, 1996; 353-364.
188. Carreño V, Quiroga JA. Tratamiento de las hepatitis crónicas por virus B y C. Farm Hosp 1996; 20: 324-327.
189. Caramelo C, Bartolomé J, Albalate M, de Sequera P, Navas S, Bermejillo T, Oliva H, Marriott E, Ortiz A, Ruiz Tuñón C, Casado S, Carreño V. Undiagnosed hepatitis C virus infection in hemodialysis patients: Value of HCV-RNA and liver enzyme levels. Kidney Int 1996; 50: 2027-2031.
190. Navas S, Castillo I, Martín J, Quiroga JA, Bartolomé J, Carreño V. Concordance of hepatitis C virus typing methods based on restriction fragment length polymorphism analysis in 5' noncoding region and NS4 serotyping, but not in core PCR or a line probe assay. J Clin Microbiol 1997; 21: 317-321.
191. Bartolomé J, Quiroga JA, Carreño V. Ultimos avances en hepatología. Hepatol Clin 1996; 4: 215-240.
192. Caramelo C, Albalate M, Bermejillo T, Navas S, Ortiz A, de Sequera P, Casado S, Carreño V. Relationships between plasma ferritin and aminotransferase profile in haemodialysis patients with hepatitis C virus. Nephrol Dial Transpl 1996; 11: 1792-1796.
193. Ruíz-Moreno M, Fernández P, Leal A, Bartolomé J, Castillo I, Oliva H, Carreño V. Pilot interferon beta trial in children with chronic hepatitis B who had previously not responded to interferon alpha therapy. Pediatrics 1997; 99: 222-225.
194. López-Alcorocho JM, Bartolomé J, Cotonat T, Carreño V. Efficacy of prolonged interferon-alpha treatment in chronic hepatitis B patients with HBeAb: comparison between 6 and 12 months of therapy. J Viral Hepatitis 1997; 4 (Suppl. 1): 27-32.
195. Castro A, Suárez D, Inglada L, Carballo E, Domínguez A, Diago M, Such J, del Olmo JA, Pérez-Mota A, Pedreira J, Quiroga JA, Carreño V. Multicenter randomized, controlled study of intramuscular administration of interferon-ß for the treatment of chronic hepatitis C. J. Interf Cytok Res 1997; 17: 27-30.
196. Moreno A, Carreño V, Cano A, González C. Idiopathic biliary ductopenia in adults without symptoms of liver disease. N Engl J Med 1997; 336: 835-838.
197. Castro A, Carballo E, Domínguez A, Diago M, Suárez D, Quiroga JA, Carreño V. Tolerance and efficacy of subcutaneous interferon-ß administered for treatment of chronic hepatitis C. J Interf Cytok Res 1997; 17: 65-67.
198. Amaro MJ, Bartolomé J, Pardo M, Cotonat T, López-Farré A, Carreño V. Decreased nitric oxide production in chronic viral hepatitis B and C. J Med Virol 1997; 51: 326-331.
199. Fernández M, Quiroga JA, Martín J, Cotonat T, Pardo M, Horisberger MA, Carreño V. Impaired interferon induction of the human MxA protein in chronic hepatitis B virus infection. J Med Virol 1997; 51: 332-337.
200. López-Alcorocho JM, Millán A, García-Trevijano ER, Bartolomé J, Ruíz-Moreno M, Otero M, Carreño V. Detection of hepatitis GB virus type C RNA in serum and liver from children with chronic viral hepatitis B and C. Hepatology 1997; 25: 1258-1260.
201. Tomás JF, Rodríguez-Iñigo E, Bartolomé J, Madejón A, Fogeda M, Oliva H, Moreno A, Fernández-Rañada JM, Carreño V. Detection Of. hepatitis G virus from serum and liver of a patient with long-term liver dysfunction after autologous bone marrow transplantation. Bone Marrow Transplant 1997; 19: 1053-1057.
202. Martín J, Quiroga JA, Carreño V. Interleuquina 12: propiedades biológicas y bases para su uso terapéutico en las infecciones crónicas por los virus B y C de la hepatitis. Hepatol Clin 1997; 5: 31-36.
203. Carreño V. Ultimos avances en hepatología. Hepatol Clin 1997; 5: 37-60.
204. de Sequera P, Caramelo C, Navas S, Goicoechea M, Bartolomé J, Bermejillo T, Albalate M, Ortiz A, Casado S, Carreño V. Hepatitis aguda por virus C (VHC) en un paciente en hemodiálisis con anticuerpos positivos: reinfección versus reactivación. Nefrología 1997; 17: 178-180.
205. Rodríguez-Iñigo E, Bartolomé J, López-Alcorocho JM, Cotonat T, Oliva H, Carreño V. Activation of liver disease in healthy hepatitis B surface antigen carriers during interferon-alpha treatment. J Med Virol 1997; 53: 76-80.
206. Rodríguez-Iñigo E, Tomás JF, Gómez-García de Soria V, Bartolomé J, Pinilla I, Amaro MJ, Carreño V, Fernández-Rañada JM. Hepatitis C and G virus infection and liver dysfunction after allogeneic bone marrow transplantation: Results from a prospective study. Blood 1997; 90: 1326-1331.
207. Madejón A, Fogeda M, Bartolomé J, Pardo M, González C, Cotonat T, Carreño V. GB virus C RNA in serum, liver, and peripheral blood mononuclear cells from patients with chronic hepatitis B, C, and D. Gastroenterology 1997; 113: 573-578.
208. Bartolomé J, Carreño V. Idiopathic Biliary Ductopenia. N Engl J Med 1997; 337: 280-281.
209. Pardo M, Carreño V. Conferencia del consenso del NIH con respecto al control de la hepatitis C. Hepatol Clin 1997; 5: 61-84.
210. Navas S, Herrero M, Pernas M, Castillo I, Martín J, Marriott E, Pardo M, Colucci G, Carreño V. Tratamiento de la hepatitis crónica C con dosis altas de interferón alfa. Hepatol Clin 1997; 5: 85-92.
211. Carreño V, Quiroga JA. Ultimos avances en hepatología. Hepatol Clin 1997; 5: 93-108.
212. Cabrerizo M, Bartolomé J, de Sequera P, Caramelo C, Carreño V. Hepatitis B virus DNA in serum and blood cells of hepatitis B surface antigen-negative hemodialysis patients and staff. J Am Soc Nephrol 1997; 8: 1443-1147.
213. Pardo M, Castillo I, Oliva H, Fernández-Flores A, Bárcena R, Antje de Peuter M, Carreño V. A pilot study of recombinant interleukin-2 for treatment of chronic hepatitis C. Hepatology 1997; 26: 1318-1321.
214. Carreño V, Quiroga JA. Biological properties of interleukin-12 and its therapeutic use in persistent hepatitis B virus and hepatitis C virus infection. J Viral Hep 1997; 4 (Suppl.2): 83-86.
215. Albalate M, García López D, Vázquez A, De Sequera P, Marriott E, Tan D, Ortiz A, Casado S, Carreño V, Caramelo C. Concentrated ascitic fluid reinfusion in cirrhotic patients: A simplified method. Am J Kidney Dis 1997; 29: 392-398.
216. Carreño V, Bartolomé J. Ultimos avances en hepatología. Hepatol Clin. 1997; 5: 143-154.
217. Navas S, Martín J, Quiroga JA, Castillo I, Carreño V. Genetic diversity and tissue compartmentalization of the hepatitis C virus genome in blood mononuclear cells, liver and serum from chronic hepatitis C patients. J Virol 1998;72:1640-1646.
218. Artillo S, Pastore G, Alberti A, Milella M, Santantonio T, Fattovich G, Giustina G, Ryff JCh, Chanéac M, Bartolomé J, Carreño V. Double-blind, randomized controlled trial of interleukin-2 treatment of chronic hepatitis B. J Med Virol 1998; 54: 167-172.
219. Martín J, Navas S, Quiroga JA, Colucci G, Pardo M, Carreño V. Quantitation of hepatitis C virus in liver and peripheral blood mononuclear cells from patients with chronic hepatitis C virus infection. J Med Virol 1998; 54: 265-270.
220. Carreño V, Castillo I, Pardo M, Quiroga JA. Ultimos avances en hepatología. Hepatol Clin 1997; 5: 189-224.
221. Ortiz A, de Sequera P, Carreño V, Caramelo C. Hepatitis B virus infection. N Engl J Med 1998; 338: 1311.
222. Gosálvez J, Rodríguez-Iñigo E, Ramiro-Díaz JL, Bartolomé J, Tomás JF, Oliva H, Carreño V. Relative quantification and mapping of hepatitis C virus by in situ hybridization and digital image analysis. Hepatology 1998; 27: 1428-1434.
223. Carreño V, Quiroga JA. Ultimos avances en hepatología. Hepatol Clin 1998; 6: 25-34.
224. Quiroga JA, Martín J, Navas S, Carreño V. Induction of interleukin-12 production in chronic hepatitis C virus infection correlates with the hepatocellular damage. J Infect Dis 1998; 178: 247-251.
225. Martín J, Navas S, Quiroga JA, Pardo M, Carreño V. Effects of the ribavirin-interferon alpha combination on cultured peripheral blood mononuclear cells from chronic hepatitis C patients. Cytokine 1998; 10: 635-644.
226. Madejón A, Bartolomé J, Carreño V. In vitro inhibition of the hepatitis delta virus replication mediated by interferon and trans-ribozyme or antisense probes. J Hepatol 1998; 29: 385-393.
227. Goicoechea M, Martín J, de Sequera P, Quiroga JA, Ortiz A, Carreño V, Caramelo C. Role of cytokines in the response to erythropoietin in hemodialysis patients. Kidney Int 1998; 54: 1337-1343.
228. Carreño V, Quiroga JA. The role of granulocyte-macrophage colony-stimulating factor in the treatment of chronic hepatitis C. Hepatol Clin 1998; 6: Suppl. 1: 113-115.
229. Pardo M, Castillo I, Carreño V. Mild idiopathic biliary ductopenia: Lack of familial clustering. J Hepatol 1998; 29: 685.
230. Cabrerizo M, Bartolomé J, Rodríguez-Iñigo E, López-Alcorocho JM, Cotonat T, Carreño V. Analysis of the hepatitis B virus precore and ORF-X sequences in patients with antibody to hepatitis B e antigen with and whithout normal ALT levels. J Med Virol 1998; 56: 294-299.
231. Krogsgaard K, the Long-term Follow-up Investigator Group and the European Study Group on Viral Hepatitis (EUROHEP). The long-term effect of treatment with interferon-alpha 2a in chronic hepatitis B. J Viral Hepat 1998; 5: 389-397.
232. Carreño V, Castillo I, Bartolomé J. Ultimos avances en hepatología. Hepatol Clin. 1998; 6: 59-88.
233. López-Alcorocho JM, Amaro MJ, Cabrerizo M, Fogeda M, Castillo I, Bartolomé J, Carreño V. Phylogenetic analysis of hepatitis GB virus type C/hepatitis G virus in Spanish patients with chronic hepatitis B or C virus infection. Intervirology 1998; 41: 233-237.
234. López-Alcorocho JM, Castillo I, Tomás JF, Carreño V. Identification of a novel GB type C virus/hepatitis G virus subtype in patients with hematologic malignancies. J Med Virol 1999; 57: 80-84.
235. Ruiz-Moreno M, Otero M, Millán A, Castillo I, Cabrerizo M, Jiménez FJ, Oliva H, Ramón y Cajal S, Carreño V. Clinical and histological outcome after hepatitis B e antigen to antibody seroconversion in children with chronic hepatitis B. Hepatology 1999; 29: 572-575.
236. Amaro MJ, Bartolomé J, Carreño V. Hepatitis B virus X protein transactivates the inducible nitric oxide synthase promoter. Hepatology 1999; 29: 915-923.
237. Martín J, Navas S, Fernández M, Rico M, Pardo M, Quiroga JA, Zahm F, Carreño V. In vitro effect of amantadine and interferon alpha 2a on hepatitis C virus markers in cultured peripheral blood mononuclear cells from hepatitis C virus infected patients. Antiviral Res 1999; 42: 59-70.
238. Zeuzem S, Hopf U, Carreño V, Diago M, Shiffman M, Grüne S, Dudley FJ, Rakhit A, Rittweger K, Yap SH, Koff RS, Thomas HC. A phase I/II study of recombinant human interleukin-12 in patients with chronic hepatitis C. Hepatology 1999; 29: 1280-1287.
239. Fogeda M, Navas S, Martín J, Casqueiro M, Rodríguez E, Arocena C, Carreño V. In vitro infection of human peripheral blood mononuclear cells by GB virus C/hepatitis G virus. J Virol 1999; 73: 4052-4061.
240. Manzano ML, Arocena C, Quiroga JA, Carreño V. Alteraciones de la coagulación en las hepatopatías crónicas. Rev Iber Tromb Hem 1999; 12: 38-40.
241. Martín J, Quiroga JA, Navas S, Pardo M, Carreño V. Modulation by biologic response modifiers of hepatitis C virus antigen-independent cytokine secretion in blood mononuclear cells. Cytokine 1999; 11: 267-273.
242. Carreño V. Ultimos avances en hepatología. Hepatol Clin. 1999; 7: 25-42.
243. Cabrerizo M, Bartolomé J, Otero M, Ruíz-Moreno M, Carreño V. Sequence variation of hepatitis B virus precore-core open reading frame isolated from serum and liver of children with chronic hepatitis B before and after interferon treatment. J Med Virol 1999; 58: 208-214.
244. Rodríguez-Iñigo E, Bartolomé J, de Lucas S, Manzarbeitia F, Pardo M, Arocena C, Gosálvez J, Oliva H, Carreño V. Histological damage in chronic hepatitis C is not related to the extent of infection in the liver. Am J Pathol 1999; 154: 1877-1881.
245. Carreño V, Marcellin P, Hadziyannis S, Salmerón J, Diago M, Kitis GE, Vafiadis I, Schalm SW, Zahm F, Manzarbeitia F, Jiménez FJ, Quiroga JA, EUROHEP. Retreatment of chronic hepatitis B e antigen-positive patients with recombinant interferon-alpha 2a. Hepatology 1999; 30: 277-282.
246. Janssen HLA, Gerken G, Carreño V, Marcellin P, Naoumov NV, Craxi A, Ring-Larsen H, Kitis G, van Hattum J, de Vries RA, Michielsen PP, ten Kate FJV, Hop WCJ, Heijtink RA, Honkoop P, Schalm SW, EUROHEP. Interferon alfa for chronic hepatitis B infection: Increased efficacy of prolonged treatment. Hepatology 1999; 30: 238-243.
247. Fernández M, Quiroga JA, Martín J, Herrero M, Pardo M, Horisberger MA, Carreño V. In vivo and in vitro induction of MxA protein in peripheral blood mononuclear cells from patients chronically infected with hepatitis C virus. J Infect Dis 1999; 180: 262-267.
248. Arocena C, Castillo I, Quiroga JA, Carreño V. Ultimos avances en hepatología. Hepatol Clin. 1999; 7: 73-100.
249. Cabrerizo M, Bartolomé J, de Sequera P, Caramelo C, Manzano ML, Carreño V. GBV-C/HGV-RNA in serum and peripheral blood mononuclear cells in hemodialysis patients. Kidney Int. 1999; 56: 1120-1128.
250. Tomás JF, Rodríguez-Iñigo E, Bartolomé J, Alegre A, Fernández-Rañada JM, Carreño V. Transplantation of allogeneic CD34-selected peripheral stem cells does not prevent transmission of hepatitis C virus from an infected donor. Bone Marrow Transplant 1999; 24: 109-112.
251. Carreño V, Castillo I. Ultimos avances en hepatología. Hepatol Clin. 1999; 7: 125-150.
252. Carreño V. Ultimos avances en hepatología. Hepatol Clin. 1999; 7: 171-206.
253. Albalate M, Martín J, de Sequera P, Quiroga JA, Olagüe C, Caramelo C, Carreño V. Cinética del interferón a-2a en pacientes en hemodiálisis. Nefrología 1999; 19: 268-270.
254. Barril G, Bartolomé J, Traver JA, Cabrerizo M, Selgas R, Carreño V. Autoclaving eliminates hepatitis C virus from a hemodialysis monitor contaminated artificially. J Med Virol 2000; 60: 139-143.
255. Cotonat T, Quiroga JA, López-Alcorocho JM, Clouet R, Pardo M, Manzarbeitia F, Carreño V. Pilot study of combination therapy with ribavirin and interferon alfa por the retreatment of chronic hepatitis B e antibody-positive patients. Hepatology 2000; 31: 502-506
256. Carreño V, Martín J, Pardo M, Brotons A Anchía P,Navas S, Fernández M, Arocena C, Quiroga JA. Randomized controlled trial of recombinant human granulocyte-macrophage colony-stimulating factor for the treatment of chronic hepatitis C. Cytokine 2000; 12: 165-170.
257. Carreño V, Zeuzem S, Hopf U, Marcellin P, Cooksley WGE, Fevery J, Diago M, Reddy R, Peters M, Rittweger K, Rakhit A, Pardo M. A phase I/II study of recombinant human interleukin-12 in patients with chronic hepatitis B. J Hepatol 2000; 32: 317-324.
258. Rodríguez-Iñigo E, Casqueiro M, Bartolomé J, Barat A, Caramelo C, Ortiz A, Albalate M, Oliva H, Manzano ML, Carreño V. Hepatitis C virus RNA in kidney biopsies from infected patients with renal diseases. J Viral Hepat 2000; 7: 23-29.
259. Rodríguez-Iñigo E, Casqueiro M, Navas S, Bartolomé J, Pardo M, Carreño V. Fluorescent "in situ" hybridization of hepatitis C virus RNA in peripheral blood mononuclear cells from patients with chronic hepatitis C. J Med Virol 2000; 60: 269-274.
260. Barril G, López-Alcorocho JM, Bajo A, Ortiz-Movilla N, Sánchez-Tomero JA, Bartolomé J, Selgas R, Carreño V. Prevalence of TT virus in serum and peripheral mononuclear cells from a capd population. Periton Dialysis Int 2000; 20: 65-68.
261. Manzano ML, Arocena C, Tomás JF, Hedner U, Quiroga JA, Carreño V. Measurement of the procoagulant activity of factor VII in patients with liver cirrhosis and normal prothrombin activity: evaluation of the bleeding risk. Blood Coag Fibrinol 2000; 11 (Suppl 1): S95-S99.
262. Rodríguez-Iñigo E, Casqueiro M, Bartolomé J, Ortiz-Movilla N, López-Alcorocho JM, Herrero M, Manzarbeitia F, Oliva H, Carreño V. Detection of TT virus DNA in liver biopsies by in situ hybridization. Am J Pathol 2000; 156: 1227-1234.
263. Arrieta JJ, Rodríguez-Iñigo E, Casqueiro M, Bartolomé J, Manzarbeitia F, Herrero M, Pardo M, Carreño V. Detection of hepatitis C virus replication by in situ hybridization in epithelial cells of anti-hepatitis C virus-positive patients with and without oral lichen planus. Hepatology 2000; 32: 97-103.
264. Madejón A, Manzano ML, Arocena C, Castillo I, Carreño V. Effects of delayed freezing of liver biopsies on the detection of hepatitis C virus RNA strands. J Hepatol 2000; 32: 1019-1025.
265. Carreño V y los miembros de la Fundación para el Estudio de las Hepatitis Virales. Ultimos avances en hepatología. Hepatol Clin. 2000; 8: 3-57.
266. Cabrerizo M, Bartolomé J, Caramelo C, Barril G, Carreño V. Molecular analysis of hepatitis B virus DNA in serum and peripheral blood mononuclear cells from hepatitis B surface antigen-negative cases. Hepatology 2000; 32: 116-123.
267. Martín J, de Sequera P, Quiroga JA, Rico M, Fernández M, Arocena C, Caramelo C, Carreño V. Role of haemodialysis and hepatitis C virus infection in spontaneous and induced cytokine production of patients with chronic renal disease. Cytokine 2000; 12: 1248-1252.
268. Fogeda M, López-Alcorocho JM, Bartolomé J, Arocena C, Martín MA, Carreño V. Existence of distinct GB virus C/hepatitis G virus variants with different tropism. J Virol 2000; 74: 7936-7942.
269. López-Alcorocho JM, Mariscal LF, de Lucas S, Rodríguez-Iñigo E, Casqueiro M, Castillo I, Bartolomé J, Herrero M, Manzano ML, Pardo M, Carreño V. Presence of TTV DNA in serum, liver and peripheral blood mononuclear cells from patients with chronic hepatitis. J Viral Hepat 2000; 7: 440-447.
270. Carreño V y los miembros de la Fundación para el Estudio de las Hepatitis Virales. Ultimos avances en hepatología. Hepatol Clin. 2000; 8: 59-104.
271. Carreño V. y los miembros de la Fundación para el Estudio de las Hepatitis Virales. Ultimos avances en hepatología. Hepatol Clin. 2000; 8: 105-146.
272. Carreño V. y los miembros de la Fundación para el Estudio de las Hepatitis Virales. Ultimos avances en hepatología. Hepatol Clin. 2000; 8:147-190.
273. Rico MA, Quiroga JA, Subirá D, Castañón S, Esteban JM, Pardo M, Carreño V. Hepatitis B virus-specific T-cell proliferation and cytokine secretion in chronic hepatitis B e antibody-positive patients treated with ribavirin and interferon-alfa. Hepatology 2001; 33: 295-300.
274. de Lucas S, Bartolomé J, Rodríguez-Iñigo E, Casqueiro M, Millán A, Ruiz-Moreno M, Oliva H, Carreño V. Distribution of hepatitis C virus infection in liver biopsies from children and adults with chronic hepatitis C. J Med Virol 2001; 64: 1-5.
275. López-Alcorocho JM, Barril G, Ortiz-Movilla N, Traver JA, Bartolomé J, Sanz P, Selgas R, Carreño V. Prevalence of hepatitis B, hepatitis C, GB virus C/hepatitis G and TT viruses in predialysis and hemodialysis patients. J Med Virol 2001; 63: 103-107.
276. Arrieta JJ, Rodríguez-Iñigo E, Ortiz-Movilla N, Bartolomé J, Pardo M, Manzarbeitia F, Oliva H, Carreño V. In situ detection of hepatitis C virus RNA in salivary glands. Am J Pathol 2001; 158: 259-264.
277. Rodríguez-Iñigo E, Bartolomé J, Quiroga JA, Hedner U, Suárez A, Tomás JF, Manzarbeitia F, Arocena C, Manzano ML, Oliva H, Carreño V. Expression of factor VII in the liver of patients with liver disease: correlations with the disease severity and impairment in the hemostasis. Blood Coag Fibrinol 2001; 12: 1-7.
278. Rodríguez-Iñigo E, Arrieta JJ, Casqueiro M, Bartolomé J, López-Alcorocho JM, Ortiz-Movilla N, Manzarbeitia F, Pardo M, Carreño V. TT virus detection in oral lichen planus lesions. J Med Virol 2001; 64: 183-189.
279. Diago M, Suárez D, García-Villarreal L, Castro A, Domínguez A, Pardo M, del Olmo JA, Pérez-Hernández F, Aguilar J, Quiroga JA, Carreño V. Multicenter randomized study comparing initial daily induction with high dose lymphoblastoid interferon vs. standard interferon treatment for chronic hepatitis C. J Med Virol 2001; 64: 460-465.
280. Carreño V, Rico MA, Pardo M, Quiroga JA. Extended follow-up of anti-HBe-positive patients with chronic hepatitis B retreated with ribavirin and interferon-alpha. Antiviral Res 2001; 52: 147-152.
281. García-Jiménez ME, Quiroga JA, Gutiérrez ML, Pardo M, Carreño V. Association of HLA-DR genes with mild idiopathic adulthood biliary ductopenia. Am J Gastroenterol 2001; 96: 1178-1182.
282. Zeuzem S, Carreño V. Interleukin-12 in the treatment of chronic hepatitis B and C. Antiviral Res 2001; 52: 181-188.
283. Rico MA, Quiroga JA, Subirá D, García E, Castañón S, Sällberg M, Leroux-Roels G, Weiland O, Pardo M, Carreño V. Features of the CD+ T-cell response in liver and peripheral blood of hepatitis C virus-infected patients with persistently normal and abnormal alanine aminotransferase levels. J Hepatol 2002; 36: 408.
284. Pardo M, Bartolomé J, Carreño V. Recombinant activated factor VII prevents bleeding during a surgical procedure in a patient with uncontrollable rectal hemorrhage. Am J Gastroenterol 2002; 97: 1266-1267.
285. Cabrerizo M, Bartolomé J, Carreño V. In vitro infection of human peripheral blood mononuclear cells by a defective hepatitis B virus with a delection in the PreS1 region of the viral genome. J Viral Hepat 2002; 9: 265-271.
286. Lazaro P, Olalquiaga J, Bartolomé J, Ortiz-Movilla N, Rodriguez-Iñigo E, Pardo M, Lecona M, Pico M, Longo I, García-Morrás P, Carreño V. Detection of hepatitis C virus RNA and core protein in keratinocytes from patients with cutaneous lichen planus and chronic hepatitis C. J Invest Dermatol 2002; 119: 798-803.
287. Olalquiaga J, Ortiz-Movilla N, Pico M, Rodriguez-Iñigo E, Lecona M, Bartolomé J, Lázaro P, Carreño V. Deteccion del virus C de la hepatitis en lesiones cutáneas de liquen plano. Mapfre Medicina 2002; 13: 81-88.
288. Ortiz-Movilla N, Lázaro P, Rodriguez-Iñigo E, Bartolomé J, Longo I, Lecona M, Pardo M, Carreño V. Hepatitis C virus replicates in sweat glands and is released into sweat in patients with chronic hepatitis C. J Med Virol 2002; 68: 529-536.
289. Mariscal LP, Lopez-Alcorocho JM, Rodriguez-Iñigo E, Ortiz-Movilla N, de Lucas S, Bartolomé J, Carreño V. TT virus replicates in stimulated but not in non-stimulated peripheral blood mononuclear cells. Virology 2002; 301: 121-129.
290. Rodriguez-Iñigo E, Mariscal L, Bartolomé J, Castillo I, Navacerrada C, Ortiz-Movilla N, Pardo M, Carreño V. Distribution of hepatitis B virus in the liver of chronic hepatitis C patients with occult hepatitis B virus infection.. J Med Virol 2003; 70: 571-580.
291. Pardo M, Sánchez J, Quemada PJ, del Corral A, Bartolomé J, Carreño V. Recombinant activated factor VII in cirrhotic patient with thrombocytopenia undergoing hip surgery prevents hemorrhages complication. World J Surgery 2003; 27: 758-759.
292. Fernández M, Quiroga JA, Carreño V. Hepatitis B virus downregulates the human interferon-inducible MxA promoter through direct interaction of precore/core proteins. J Gen Virol 2003; 84: 2073-2082.
293. Gósalvez J, Ortiz-Movilla N, Gosálbez A, Rodríguez-Iñigo E, Bartolomé J, Carreño V. Improved sensitivity for cell mapping of hepatitis C virus RNA sequences and cellular surface antigens in blood cells. Lab Invest 2003; 83: 1089-091.
294. Castillo I, Pardo M, Bartolomé J, Ortiz-Movilla N, Rodriguez-Iñigo E, de Lucas S, Salas C, Jiménez-Hefferman JA, Pérez-Mota A, Graus J, López-Alcorocho JM, Carreño V. Occult hepatitis C virus infection in patients in whom the etiology of persistently abnormal results of liver-function tests is unknown. J Infect Dis 2004; 189: 7-14.
295. Rico MA, Ruiz S, Subirá D, Barril G, Cigarrán S, Castañón S, Quiroga JA, Selgas R, Carreño V. Virus-specific effector CD4+ T-cell responses in hemodialysis patients with hepatitis C virus infection. J Med Virol 2004; 72: 66-74.
296. Mariscal LP, Rodríguez-Iñigo E, Bartolomé J, Castillo I, Ortiz-Movilla N, Navacerrada C, Pardo M, Pérez-Mota A, Graus J, Carreño V. Hepatitis B infection of the liver in chronic hepatitis C without detectable hepatitis B virus DNA in serum. J Med Virol 2004; 73: 177-86.
297. Bartolomé J, Castillo I, Carreño V. Ribozymes as antiviral agents. J Minerva Medica 2004; 95: 11-24. Review.
298. Hultgren C, Desombere I, Leroux-Roels G, Quiroga JA, Carreno V, Nilsson B, Weiland O, Sällberg M. Evidence for a relation between the viral load and genotype and hepatitis C virus-specific T cell responses. J Hepatol 2004;40:971-8.
299. Mariscal LF, Rodríguez-Iñigo E, Bartolomé J, Castillo I, Ortiz-Movilla N, Navacerrada C, Pardo M, Pérez-Mota A, Graus J, Carreño V. Hepatitis B infection of the liver in chronic hepatitis C without detectable hepatitis B virus DNA in serum. J Med Virol 2004;73:177-86.
300. Barril G, González Parra E, Alcázar R, Arenas D, Campistol JM, Caramelo C, Carrasco M, Carreño V, Espinosa M, García Valdecasas J, Górriz JL, López MD, Martín L, Ruiz P, Terruel JL; Spanish Society of Nephrology.[Guidelines on hemodialysis-associated viral infections] Nefrologia 2004;24 Suppl 2:43-66. Review.
301. Carreño V, Castillo I, Bartolomé J, Rodríguez-Iñigo E, Ortiz-Movilla N, de Lucas S, Pardo M. Comparison of hepatitis C virus RNA detection in plasma, whole blood and peripheral blood mononuclear cells of patients with occult hepatitis C virus infection. J Clin Virol 2004;31:312-3.
302. Lucas Sd S, López-Alcorocho JM, Bartolomé J, Carreño V. Nitric oxide and TGF-beta1 inhibit HNF-4alpha function in HEPG2 cells. Biochem Biophys Res Commun 2004;321:688-94.
303. Barril G, Quiroga JA, Sanz P, Rodrìguez-Salvanés F, Selgas R, Carreño V. Pegylated interferon-alpha2a kinetics during experimental haemodialysis: impact of permeability and pore size of dialysers. Aliment Pharmacol Ther 2004;20:37-44.
304. Quiroga JA, Carreño V. HCV-indeterminate blood donors or occult HCV infection? Lancet 2005;365:1540-1.
305. Castillo I, Rodríguez-Iñigo E, Bartolomé J, de Lucas S, Ortíz-Movilla N, López-Alcorocho JM, Pardo M, Carreño V. Hepatitis C virus replicates in peripheral blood mononuclear cells of patients with occult hepatitis C virus infection. Gut 2005;54:682-5.
306. de Lucas S, Bartolome J, Carreno V. Hepatitis C virus core protein down-regulates transcription of interferon-induced antiviral genes. J Infect Dis 2005;19:93-9.
307. Rodríguez-Iñigo E, Bartolomé J, Ortiz-Movilla N, Platero C, López-Alcorocho JM, Pardo M, Castillo I, Carreño V. Hepatitis C virus (HCV) and hepatitis B virus (HBV) can coinfect the same hepatocyte in the liver of patients with chronic HCV and occult HBV infection. J Virol 2005;79:15578-81.
308. Rodríguez-Iñigo E, López-Alcorocho JM, Bartolomé J, Ortiz-Movilla N, Pardo M, Carreño V. Percentage of hepatitis C virus-infected hepatocytes is a better predictor of response than serum viremia levels. J Mol Diagn 2005;7:535-43.
309. Rodríguez-Iñigo E, Jiménez E, Bartolomé J, Ortiz-Movilla N, Bartolomé Villar B, José Arrieta J, Manzarbeitia F, Carreño V. Detection of human immunodeficiency virus type 1 RNA by in situ hybridization in oral mucosa epithelial cells from anti-HIV-1 positive patients. J Med Virol 2005;77:17-22.
310. Carreño V, Pardo M, López-Alcorocho JM, Rodríguez-Iñigo E, Bartolomé J, Castillo I. Detection of hepatitis C virus (HCV) RNA in the liver of healthy, anti-HCV antibody-positive, serum HCV RNA-negative patients with normal alanine aminotransferase levels. J Infect Dis 2006;194:53-60.
311. Pardo M, López-Alcorocho JM, Castillo I, Rodríguez-Iñigo E, Perez-Mota A, Carreño V. Effect of anti-viral therapy for occult hepatitis C virus infection. Aliment Pharmacol Ther 2006;23:1153-9.
312. Rodríguez-Casado A, Bartolomé J, Carreño V, Molina M, Carmona P. Structural characterization of the 5' untranslated RNA of hepatitis C virus by vibrational spectroscopy. Biophys Chem 2006;124:73-9..
313. Quiroga JA, Llorente S, Castillo I, Rodríguez-Iñigo E, López-Alcorocho JM, Pardo M, Carreño V. Virus-specific T-cell responses associated with hepatitis C virus (HCV) persistence in the liver after apparent recovery from HCV infection. J Med Virol 2006;78:1190-7.
314. Castillo I, Rodríguez-Iñigo E, López-Alcorocho JM, Pardo M, Bartolomé J, Carreño V Hepatitis C virus replicates in the liver of patients who have a sustained response to antiviral treatment. Clin Infect Dis 2006;43:1277-83.
315. Quiroga JA, Castillo I, Pardo M, Rodríguez-Iñigo E, Carreño V. Combined hepatitis C virus (HCV) antigen-antibody detection assay does not improve diagnosis for seronegative individuals with occult HCV infection. J Clin Microbiol 2006;44:4559-60.
316. Quiroga JA, Llorente S, Castillo I, Rodríguez-Iñigo E, Pardo M, Carreño V. Cellular immune responses associated with occult hepatitis C virus infection of the liver. J Virol 2006;80:10972-9.
317. Carreño V. Occult hepatitis C virus infection: a new form of hepatitis C. World J Gastroenterol 2006;12:6922-5.
318. López-Alcorocho JM, Rodríguez-Iñigo E, Castillo I, Castellanos ME, Pardo M, Bartolomé J, Quiroga JA, Carreño V. The role of genomic and antigenomic HCV-RNA strands as predictive factors of response to pegylated interferon plus ribavirin therapy. Aliment Pharmacol Ther 2007;25:1193-201.
319. Castillo I, Rodríguez-Iñigo E, López-Alcorocho JM, Bartolomé J, Pardo M, Carreño V. Comparative study on the clinical and virological characteristics among patients with single occult hepatitis B virus (HBV), single occult hepatitis C virus (HCV) and occult HBV and HCV dual infection. J Med Virol 2007;79:236-41.
320. Pardo M, López-Alcorocho JM, Rodríguez-Iñigo E, Castillo I, Carreño V. Comparative study between occult hepatitis C virus infection and chronic hepatitis C. J Viral Hepat 2007;14:36-40.
321. Bartolomé J, López-Alcorocho JM, Castillo I, Rodríguez-Iñigo E, Quiroga JA, Palacios R, Carreño V. Ultracentrifugation of serum samples allows detection of hepatitis C virus RNA in patients with occult hepatitis C. J Virol 2007;81:7710-5.
322. Desombere I, Van Vlierberghe H, Weiland O, Hultgren C, Sällberg M, Quiroga J, Carreño V, Leroux-Roels G. Serum levels of anti-NS4a and anti-NS5a predict treatment response of patients with chronic hepatitis C. J Med Virol 2007;79:701-13.
323. Pardo M, Bartolomé J, Carreño V. Current therapy of chronic hepatitis B. Arch Med Res 2007;38:661-77. Review.
324. Quiroga JA, Castillo I, Bartolomé J, Carreño V. Serum immunoglobulin G antibodies to the GOR autoepitope are present in patients with occult hepatitis C virus (HCV) infection despite lack of HCV-specific antibodies. Clin Vaccine Immunol 2007;14:1302-6.Virol 2006 (in press).
325. Bartolomé J, Rodríguez-Iñigo E, Erice A, Vidal S, Castillo I, Carreño V. Hepatitis C virus does not infect muscle, the intervertebral disk, or the meniscus in patients with chronic hepatitis C. J Med Virol 2007;79:1818-20.
326. Carreño V, Bartolomé J, Castillo I, Quiroga JA. Occult hepatitis B virus and hepatitis C virus infections. Rev Med Virol 2008;18:139-57. Review.
327. Bartolomé J, Rodríguez-Iñigo E, Quadros P, Vidal S, Pascual-Miguelañez I, Rodríguez-Montes JA, García-Sancho L, Carreño V. Detection of hepatitis C virus in thyroid tissue from patients with chronic HCV infection. J Med Virol 2008;80:1588-94.
328. Barril G, Castillo I, Arenas MD, Espinosa M, Garcia-Valdecasas J, Garcia-Fernández N, González-Parra E, Alcazar JM, Sánchez C, Diez-Baylón JC, Martinez P, Bartolomé J, Carreño V. Occult Hepatitis C Virus Infection among Hemodialysis Patients. J Am Soc Nephrol 2008 Dec;19(12):2288-92. Epub 2008 Aug 6.
329. Does occult hepatitis C virus infection exist? Carreño V, Bartolomé J, Castillo I, Quiroga JA.J Clin Microbiol. 2008 Oct;46(10):3550; author reply 3550-2. No abstract available.
330. Identification of serologically silent occult hepatitis C virus infection by detecting immunoglobulin G antibody to a dominant HCV core peptide epitope. Quiroga JA, Castillo I, Llorente S, Bartolomé J, Barril G, Carreño V.J Hepatol. 2009 Feb;50(2):256-63. Epub 2008 Nov 4.
331. Hepatitis C virus infection in the family setting of patients with occult hepatitis C. Castillo I, Bartolomé J, Quiroga JA, Barril G, Carreño V. J Med Virol. 2009 Jul;81(7):1198-203.
332. Hepatitis C virus replication in patients with occult hepatitis C virus infection. Carreño V, Bartolomé J, Castillo I, Quiroga JA. Hepatology. 2009 Jun;49(6):2128-9
333. Presence of HCV-RNA after ultracentrifugation of serum samples during the follow-up of chronic hepatitis C patients with a sustained virological response may predict reactivation of hepatitis C virus infection. Castillo I, Bartolomé J, Quiroga JA, Barril G, Carreño V. Aliment Pharmacol Ther. 2009 Sep 1;30(5):477-86
334. An unusual case of cholelithiasis. Bartolomé J, Castillo I, Quiroga JA, Carreno V.J Clin Virol. 2009 Nov;46(3):199-200.
335. Evidence of occult hepatitis C virus infection in hemodialysis patients. Barril G, Castillo I, Carreño V.Am J Kidney Dis. 2009 Nov;54(5):980-1
336. Effect of hemodialysis schedules and membranes on hepatocyte growth factor and hepatitis C virus RNA levels. Barril G, Bartolomé J, Sanz P, Buoncristiani E, Traver JA, Selgas R, Buoncristiani U, Castillo I, Quiroga JA, Carreño V. J Med Virol. 2010 May;82(5):763-7.
337. Diagnosis of occult hepatitis C without the need for a liver biopsy. Castillo I, Bartolomé J, Quiroga JA, Barril G, Carreño V. J Med Virol. 2010 Sep;82(9):1554-9.